Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 7177.0 | 76 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 6752.5 | 80 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 3077.0 | 51 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 8935.5 | 54 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 6895.0 | 54 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 158.0 | 68 | |
RA2159 | PI103 | 0.1 | uM | 1 | RANTES | 81.0 | 63 | ||||
N2586 | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 11037.0 | 47 | ||||
N2586 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 12141.5 | 70 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 8186.5 | 42 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 14344.0 | 53 | |
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 13673.5 | 58 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | RANTES | 1967.5 | 42 | |
N2586 | PI103 | 0.1 | uM | 1 | RANTES | 93.0 | 82 | ||||
RA2159 | IL-6 | 100 | ug/mL | 1 | RANTES | 178.0 | 66 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 110.0 | 69 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 69.0 | 63 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 78.0 | 81 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 83.5 | 60 | |
RA2159 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 78.0 | 55 | |
RA2159 | Sigma A6730 | 3.0 | uM | 1 | RANTES | 64.0 | 53 | ||||
N2586 | IL-6 | 100 | ug/mL | 1 | RANTES | 60.0 | 71 | ||||
N2586 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 56.5 | 62 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 49.0 | 42 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | RANTES | 99.0 | 48 |